@article{498fdf72f4ea4a01851acb0df8d3b959,
title = "Recommendations for measuring HIV reservoir size in cure-directed clinical trials",
abstract = "Therapeutic strategies are being clinically tested either to eradicate latent HIV reservoirs or to achieve virologic control in the absence of antiretroviral therapy. Attaining this goal will require a consensus on how best to measure the numbers of persistently infected cells with the potential to cause viral rebound after antiretroviral-therapy cessation in assessing the results of cure-directed strategies in vivo. Current measurements assess various aspects of the HIV provirus and its functionality and produce divergent results. Here, we provide recommendations from the BEAT-HIV Martin Delaney Collaboratory on which viral measurements should be prioritized in HIV-cure-directed clinical trials.",
author = "{The BEAT-HIV Delaney Collaboratory to Cure HIV-1 infection} and Mohamed Abdel-Mohsen and Douglas Richman and Siliciano, {Robert F.} and Nussenzweig, {Michel C.} and Howell, {Bonnie J.} and Javier Martinez-Picado and Nicolas Chomont and Bar, {Katharine J.} and Yu, {Xu G.} and Mathias Lichterfeld and Jose Alcami and Daria Hazuda and Frederic Bushman and Siliciano, {Janet D.} and Betts, {Michael R.} and Spivak, {Adam M.} and Vicente Planelles and Hahn, {Beatrice H.} and Smith, {Davey M.} and Ho, {Ya Chi} and Buzon, {Maria J.} and Christian Gaebler and Mirko Paiardini and Qingsheng Li and Estes, {Jacob D.} and Hope, {Thomas J.} and Jay Kostman and Karam Mounzer and Marina Caskey and Lawrence Fox and Ian Frank and Riley, {James L.} and Pablo Tebas and Montaner, {Luis J.} and Mohamed Abdel-Mohsen",
note = "Publisher Copyright: {\textcopyright} 2020, Springer Nature America, Inc.",
year = "2020",
month = sep,
day = "1",
doi = "10.1038/s41591-020-1022-1",
language = "English (US)",
volume = "26",
pages = "1339--1350",
journal = "Nature medicine",
issn = "1078-8956",
publisher = "Nature Publishing Group",
number = "9",
}